Brief: OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
04/12/2024 14:10
Dec 4 (Reuters) -
* OMNISCIENCE INC. AND INMUNE BIO INC. PARTNER TO ACCELERATE
A
PHASE 2 ALZHEIMER’S TRIAL WITH VIVO, A NOVEL GENAI CLINICAL
TRIAL CONTROL TOWER
Source text: ID:nBw5hD15a
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview